

个人简历

姓 名	罗佩琼	性 别	女
民 族	汉	出生年月	1993.01.26
邮 箱	lorenelpq0126@163.com	电 话	17391726109
婚姻状况	未婚	学 历 水 平	博士
籍 贯	陕西宝鸡	专 业	内分泌



教育背景

本科 2012.09 ~ 2017.07: 郑州大学临床医学院 临床医学系

硕士 2017.09 ~ 2020.07: (推免) 四川大学华西临床医学院 内分泌与代谢 专业型硕士 导师: 安振梅教授

博士 2021.09 ~ 至今: 华中科技大学同济医学院 内分泌与代谢 科研型博士 导师: 余学锋教授

独立第一作者文章

1. **Luo P**, et, al. Associations of Physiologic Subtypes Based on HOMA2 Indices of β -cell Function and Insulin Sensitivity with the Risk of Kidney Function Decline, Cardiovascular Disease, and All-cause Mortality from the 4C Study. **Cardiovascular Diabetology (IF 8.5 JCR Q1)**. 23, 401 (2024). doi: 10.1186/s12933-024-02496-5.
2. **Luo P**, et, al. ENPP2/Autotaxin: The potential drug target for alcoholic liver disease identified through Mendelian randomization analysis. **Liver International (IF 6.7 JCR Q1)**. March 22, 2024. doi:10.1111/liv.15905.
3. **Luo P**, et, al. Progress in the Pathogenesis, Diagnosis, and Treatment of TSH-Secreting Pituitary Neuroendocrine Tumor. **Frontiers in Endocrinology (IF 3.9 JCR Q2)**. 2020 Nov 27. doi: 10.3389/fendo.2020.580264.
4. **Luo P**, et, al. The mediating role of remnant cholesterol in the associations of Angiopoietin-like 8 with all-cause, CVD, and cancer death: the China Cardiometabolic Disease and Cancer Cohort (4C) study. **Endocrine (IF 3 JCR Q2)**. 27 Nov. 2024, doi:10.1007/s12020-024-04115-5.
5. **Luo P**, et, al. Association between estimated glucose disposal rate and kidney function decline in different glucose tolerance statuses from 4C cohort study. **Acta Diabetologica (IF 3.1 JCR Q2)**.18 Dec. 2024, doi:10.1007/s00592-024-02432-9.
6. **Luo P**, et, al. The modified role including mediating and synergistic interactive effects of glucose tolerance status in the associations between relative fat mass and the risks of cardiovascular disease and all-cause mortality from the 4C cohort study. **Diabetology & metabolic syndrome (IF 3.4 JCR Q2)** vol. 16,1 313. 26 Dec. 2024, doi:10.1186/s13098-024-01558-8.
7. **Luo P**, et, al. Associations between the triglyceride-glucose index and kidney function decline, cardiovascular disease events, and all-cause mortality in different glucose tolerance statuses. **BMJ Open. (UNDER REVIEW) (IF 2.4 JCR Q2)**.

科研经历

2021.09 ~ 至今: 脂肪肝发病机制相关基础实验的研究, 临床队列机器学习研究 (R 语言, Python 编程), 孟德尔药物靶点研究等;

2018.07~ 2019.09: 14L-GJ-ABET 临床研究方案(a)在中国成年 2 型糖尿病患者中比较长效基础胰岛素类似物 LY2963016 与来得时的前瞻性、随机、开放研究

专业证书及获奖经历

CET6: 552; IELTS: 6.5

医师资格证书、医师执业证书(2018-10); 住院医师规范化培训合格证书(2020-07); 四川大学药物临床试验 GCP 证书(2017-12)

博士: 一等学业奖学金 3 次; 硕士: 2 次校级二等奖学金; 本科: 1 次校级二等奖学金, 3 次校级三等奖学金